ResearcherFox Chase Cancer CenterNo recent work listed

Maitham A. Moslim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5755-9388; OpenAlex author ID A5034898420. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper

Papers 2

Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improved Ratio. Co-author DOI 10.1016/j.jss.2022.08.002 ↗
Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? Co-author DOI 10.5306/wjco.v12.i2.54 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Sanjay S. Reddy · 2 shared papers, 2021–2022 · strength 0.37
- Paper Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? DOI 10.5306/wjco.v12.i2.54 ↗
- Paper Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improv… DOI 10.1016/j.jss.2022.08.002 ↗
Michael J. Hall · 1 shared paper, 2021 · strength 0.19
- Paper Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? DOI 10.5306/wjco.v12.i2.54 ↗
Joshua E. Meyer · 1 shared paper, 2021 · strength 0.19
- Paper Pancreatic cancer in the era of COVID-19 pandemic: Which one is the lesser of two evils? DOI 10.5306/wjco.v12.i2.54 ↗
Dany Barrak · 1 shared paper, 2022 · strength 0.17
- Paper Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improv… DOI 10.1016/j.jss.2022.08.002 ↗
Anthony M. Villano · 1 shared paper, 2022 · strength 0.17
- Paper Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improv… DOI 10.1016/j.jss.2022.08.002 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.